PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

NCT03327740 · clinicaltrials.gov ↗

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus I

Interventions

DRUG: DTG based ARV regimen with ABC
DRUG: DTG based ARV regimen without ABC
DRUG: RAL or EGV based ARV regimens with ABC
DRUG: RAL or EGV based regimens without ABC
DRUG: Any other DTG based ARV regimen as monotherapy

Sponsor

ViiV Healthcare

Collaborators

[object Object]